Find Zuranolone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Sage-217, 1632051-40-1, Zuranolone [inn], Zuranolone [usan], Sge-797, Chembl4105630
Molecular Formula
C25H35N3O2
Molecular Weight
409.6  g/mol
InChI Key
HARRKNSQXBRBGZ-GVKWWOCJSA-N
FDA UNII
7ZW49N180B

Zuranolone
1 2D Structure

Zuranolone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile
2.1.2 InChI
InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
2.1.3 InChI Key
HARRKNSQXBRBGZ-GVKWWOCJSA-N
2.1.4 Canonical SMILES
CC1(CCC2C(C1)CCC3C2CCC4(C3CCC4C(=O)CN5C=C(C=N5)C#N)C)O
2.1.5 Isomeric SMILES
C[C@]1(CC[C@H]2[C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CN5C=C(C=N5)C#N)C)O
2.2 Other Identifiers
2.2.1 UNII
7ZW49N180B
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(3.alpha.-hydroxy-3.beta.-methyl-20-oxo-19-nor-5.beta.-pregnan-21-yl)-1h-pyrazole-4-carbonitrile

2. 1h-pyrazole-4-carbonitrile, 1-((3.alpha.,5.beta.)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl)-

3. 3alpha-hydroxy-3beta-methyl-21-(4-cyano-1h-pyrazol-1'-yl)-19-nor-5beta-pregnan-20-one

4. 3beta-methyl-21-(4-cyano-1h-pyrazol-1'-yl)-19-norpregnanolone

5. Sage-217

2.3.2 Depositor-Supplied Synonyms

1. Sage-217

2. 1632051-40-1

3. Zuranolone [inn]

4. Zuranolone [usan]

5. Sge-797

6. Chembl4105630

7. 7zw49n180b

8. S-812217

9. 1-[2-[(3r,5r,8r,9r,10s,13s,14s,17s)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile

10. Zuranolonesage-217

11. Zuranolone (usan/inn)

12. Unii-7zw49n180b

13. Schembl16189866

14. Dtxsid601128500

15. Glxc-15028

16. Amy27908

17. Ex-a1880

18. Bdbm50258216

19. Who 10896

20. Akos037648887

21. Db15490

22. Ac-35591

23. Bs-15950

24. Hy-103040

25. Cs-0023489

26. D11793

27. D80690

28. A905859

29. 3beta-methyl-21-(4-cyano-1h-pyrazol-1'-yl)-19-norpregnanolone

30. 3alpha-hydroxy-3beta-methyl-21-(4-cyano-1h-pyrazol-1'-yl)-19-nor-5beta-pregnan-20-one

31. 1-(2-((3r,5r,8r,9r,10s,13s,14s,17s)-3-hydroxy-3,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1h-pyrazole-4-carbonitrile

32. 1-(2-((3r,5r,8r,9r,10s,13s,14s,17s)-3-hydroxy-3,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1h-pyrazole-4-carbonitrile;1-[(3alpha,5beta)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl]-1h-pyrazole-4-carbonitrile

33. 1-(3.alpha.-hydroxy-3.beta.-methyl-20-oxo-19-nor-5.beta.-pregnan-21-yl)-1h-pyrazole-4-carbonitrile

34. 1-(3alpha-hydroxy-3beta-methyl-20-oxo-19-nor-5beta-pregnan-21-yl)-1h-pyrazole-4-carbonitrile

35. 1h-pyrazole-4-carbonitrile, 1-((3.alpha.,5.beta.)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl)-

36. 1h-pyrazole-4-carbonitrile, 1-((3alpha,5beta)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl)-

2.4 Create Date
2014-12-29
3 Chemical and Physical Properties
Molecular Weight 409.6 g/mol
Molecular Formula C25H35N3O2
XLogP34.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass409.27292737 g/mol
Monoisotopic Mass409.27292737 g/mol
Topological Polar Surface Area78.9 Ų
Heavy Atom Count30
Formal Charge0
Complexity746
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PharmaVenue
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PharmaVenue
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

03

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

04

Curia

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow

05

Beijing Sjar Technology Developmen...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Zurzuvae (zuranolone), the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD.


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: Zurzuvae

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Sage Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 14, 2023

blank

01

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Zurzuvae (zuranolone), the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD.

Brand Name : Zurzuvae

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 14, 2023

blank

Details:

Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum depression.


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: Zurzuvae

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2023

blank

02

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum dep...

Brand Name : Zurzuvae

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 31, 2023

blank

Details:

Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum depression.


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: Zurzuvae

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 04, 2023

blank

03

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum dep...

Brand Name : Zurzuvae

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 04, 2023

blank

Details:

SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Sage Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2023

blank

04

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 08, 2023

blank

Details:

SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Biogen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 06, 2023

blank

05

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 06, 2023

blank

Details:

SAGE-217 (zuranolone) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM).


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Sage Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 06, 2022

blank

06

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Biogen

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : SAGE-217 (zuranolone) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric m...

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 06, 2022

blank

Details:

Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported.


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Sage Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 17, 2022

blank

07

Biogen

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Biogen

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported.

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 17, 2022

blank

Details:

Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Biogen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 19, 2022

blank

08

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 19, 2022

blank

Details:

SAGE-217 (zuranolone), 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints.


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Biogen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

blank

09

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : SAGE-217 (zuranolone), 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints.

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 01, 2022

blank

Details:

SAGE-217 (zuranolone) is an investigational oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes to regulating brain function.


Lead Product(s): Zuranolone

Therapeutic Area: Psychiatry/Psychology Brand Name: SAGE-217

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Biogen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

blank

10

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : SAGE-217 (zuranolone) is an investigational oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes to regulatin...

Brand Name : SAGE-217

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 01, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

LinkChem

China
Pharmatech Expo 2025
Not Confirmed
arrow

LinkChem

China
Pharmatech Expo 2025
Not Confirmed
arrow

CAS Number : 1430063-93-6

End Use API : Zuranolone

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

BIOGEN INC

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

BIOGEN INC

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

ZURANOLONE

Brand Name : ZURZUVAE

Dosage Form : CAPSULE;ORAL

Dosage Strength : 20MG

Approval Date : 2023-10-31

Application Number : 217369

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

BIOGEN INC

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

BIOGEN INC

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

ZURANOLONE

Brand Name : ZURZUVAE

Dosage Form : CAPSULE;ORAL

Dosage Strength : 25MG

Approval Date : 2023-10-31

Application Number : 217369

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

03

BIOGEN INC

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

BIOGEN INC

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

ZURANOLONE

Brand Name : ZURZUVAE

Dosage Form : CAPSULE;ORAL

Dosage Strength : 30MG

Approval Date : 2023-10-31

Application Number : 217369

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 11884696

Drug Substance Claim :

Drug Product Claim :

Application Number : 217369

Patent Use Code : U-2552

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-24

blank

02

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 9512165

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217369

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-04-17

blank

03

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 11884696

Drug Substance Claim :

Drug Product Claim :

Application Number : 217369

Patent Use Code : U-2552

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-24

blank

04

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 9512165

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217369

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-04-17

blank

05

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 11884696

Drug Substance Claim :

Drug Product Claim :

Application Number : 217369

Patent Use Code : U-2552

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-24

blank

06

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 11236121

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 217369

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-08-23

blank

07

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 10342810

Drug Substance Claim :

Drug Product Claim :

Application Number : 217369

Patent Use Code : U-2552

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-04-17

blank

08

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 11236121

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 217369

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-08-23

blank

09

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 10342810

Drug Substance Claim :

Drug Product Claim :

Application Number : 217369

Patent Use Code : U-2552

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-04-17

blank

10

arrow
Pharmatech Expo 2025
Not Confirmed

BIOGEN INC

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

ZURANOLONE

US Patent Number : 11236121

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 217369

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-08-23

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

SAGE-217 Manufacturers

A SAGE-217 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SAGE-217, including repackagers and relabelers. The FDA regulates SAGE-217 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SAGE-217 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of SAGE-217 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

SAGE-217 Suppliers

A SAGE-217 supplier is an individual or a company that provides SAGE-217 active pharmaceutical ingredient (API) or SAGE-217 finished formulations upon request. The SAGE-217 suppliers may include SAGE-217 API manufacturers, exporters, distributors and traders.

click here to find a list of SAGE-217 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

SAGE-217 NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing SAGE-217 as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for SAGE-217 API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture SAGE-217 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain SAGE-217 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a SAGE-217 NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of SAGE-217 suppliers with NDC on PharmaCompass.

SAGE-217 GMP

SAGE-217 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of SAGE-217 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right SAGE-217 GMP manufacturer or SAGE-217 GMP API supplier for your needs.

SAGE-217 CoA

A SAGE-217 CoA (Certificate of Analysis) is a formal document that attests to SAGE-217's compliance with SAGE-217 specifications and serves as a tool for batch-level quality control.

SAGE-217 CoA mostly includes findings from lab analyses of a specific batch. For each SAGE-217 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

SAGE-217 may be tested according to a variety of international standards, such as European Pharmacopoeia (SAGE-217 EP), SAGE-217 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (SAGE-217 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty